Dizhe Pharmaceuticals (688192.SH): Positive top-line results from international multicenter phase III clinical trial of Shuwozhe monotherapy for EGFRexon20ins non-small cell lung cancer.

15:43 22/03/2026

Dizhe Pharmaceuticals (688192.SH) announced that the company's independently developed product Shuwuzhe (ZEGFROVY, generic name: Shuwotini tablets) has achieved positive top-line results in the international multicenter phase III clinical study "Wu-Kong 28" for the first-line treatment of EGFR exon 20 insertion mutation (exon20ins) advanced non-small cell lung cancer (NSCLC). This is the world's first and only oral targeted drug to achieve positive results in an international multicenter, randomized controlled phase III clinical study for first-line treatment of EGFR exon20ins NSCLC.

Di Zhe Pharmaceuticals (688192.SH) announced that the company's independently developed product Shuwuzhe (ZEGFROVY, generic name: Shuwotini tablet) has achieved the primary research endpoint and obtained positive top-line results in the international multicenter Phase III clinical study "Wukong28" for the first-line treatment of epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon20ins) advanced non-small cell lung cancer (NSCLC). It is the first and only oral targeted drug to achieve positive results in international multicenter randomized controlled Phase III clinical studies targeting EGFRexon20ins NSCLC in the world.

China Micro Semicon (Shenzhen) (688380.SH) plans to invest 160 million yuan to increase capital in the chip design company Zhuhai Boya to strengthen cooperation.

Guangdong Hongda Holdings Group, the controlling shareholder of Xinjiang Xuefeng Sci-Tech (603227.SH), plans to increase its holdings by 150 million to 300 million yuan.

HaiXin Foods (002702.SZ) controlling shareholder Teng Yongxiong and concerted parties intend to reduce their shareholding by no more than 1%.

China Micro Semicon (Shenzhen) (688380.SH) plans to invest 160 million yuan to increase capital in the chip design company Zhuhai Boya to strengthen cooperation.

Guangdong Hongda Holdings Group, the controlling shareholder of Xinjiang Xuefeng Sci-Tech (603227.SH), plans to increase its holdings by 150 million to 300 million yuan.

HaiXin Foods (002702.SZ) controlling shareholder Teng Yongxiong and concerted parties intend to reduce their shareholding by no more than 1%.